Bicycle Therapeutics plc

Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing a novel class of precision-guided medicines, known as Bicycle® molecules, to address diseases currently underserved by existing therapeutics. The company's core mission is to become a leading entity in solid tumor medicines, leveraging its proprietary bicyclic peptide technology. Bicycle Therapeutics operates as a transatlantic company, with its headquarters located in Cambridge, UK, and significant operational presence, including key leadership functions, in Boston/Lexington, Massachusetts, USA.

The company's innovative Bicycle® molecules are fully synthetic short peptides engineered with small molecule scaffolds to form two stable loops. This unique structural constraint is designed to confer high affinity and selectivity, enabling deep tissue penetration and combining the pharmacological advantages of biologics with the synthetic and pharmacokinetic benefits of small molecules. Bicycle Therapeutics primarily targets oncology, particularly solid tumors, and its pipeline includes Bicycle® Drug Conjugates (BDCs), Bicycle® Radioconjugates (BRCs), and Bicycle® Tumor-Targeted Immune Cell Agonists (Bicycle® TICAs). Key product candidates include nuzefatide pevedotin (formerly BT5528), a BDC targeting EphA2, currently in Phase 2 for pancreatic cancer, and zelenectide pevedotin (formerly BT8009), a BDC targeting Nectin-4.

In March 2026, Bicycle Therapeutics initiated a strategic reprioritization to concentrate its resources on its most promising next-generation therapeutics, including nuzefatide and its emerging BRC pipeline. This strategic shift involved discontinuing certain zelenectide trials and an anticipated workforce reduction of approximately 30%. Kevin Lee serves as the Chief Executive Officer, a role he has held since September 2015, with recent leadership changes in February 2026 bringing Travis Thompson as CFO, Michael Method as CMO, and Michael Skynner as CSO. The company reported a net loss of $60.8 million for Q1 2026, with cash and cash equivalents totaling $559.5 million, providing a projected cash runway into 2030. Q1 2026 revenue was $0.887 million, falling short of analyst estimates.

Latest updates

Bicycle Therapeutics Pivots, Cuts Workforce Amid Nuzefatide Progress

Event summary

  • Bicycle Therapeutics reported Q1 2026 revenue of $0.9 million, down from $10.0 million in Q1 2025, due to terminated collaborations.
  • The company is initiating a workforce reduction of approximately 30%, anticipating $50 million in annual savings.
  • Phase 1/2 data for nuzefatide pevedotin in combination with nivolumab showed a 40% ORR in EphA2+ mUC patients.
  • Bicycle Therapeutics is converting the Duravelo-2 trial to a randomized Phase 2 trial and prioritizing nuzefatide and radiotherapeutics.
  • The company now projects a cash runway extending into 2030 following the restructuring.

The big picture

Bicycle Therapeutics' strategic pivot reflects a broader trend in the biotech sector, where companies are increasingly forced to prioritize pipelines and cut costs amid market volatility. The company's focus on nuzefatide, a potentially first-in-class EphA2 targeting drug conjugate, represents a high-risk, high-reward bet on a historically undruggable target. The company's ability to demonstrate clinical efficacy and secure regulatory approval will be crucial for its long-term viability.

What we're watching

Clinical Efficacy
The success of the Phase 2 trial for nuzefatide in pancreatic cancer will be critical in validating the drug's potential and justifying further investment, given the historical difficulty in targeting EphA2.
Financial Stability
Whether the cost savings from the workforce reduction and strategic shift will be sufficient to sustain operations until potential future revenue streams materialize remains a key risk.
Regulatory Path
The feedback from regulatory agencies regarding the development path for zelenectide will dictate whether Bicycle Therapeutics can leverage the promising early data or must abandon the program.

Bicycle Therapeutics to Present Urothelial Carcinoma Data at ASCO 2026

Event summary

  • Bicycle Therapeutics will present oral and poster data at the ASCO 2026 Annual Meeting, June 1-2 in Chicago.
  • Key data focuses on zelenectide pevedotin (BT8009) in combination with pembrolizumab and as a monotherapy for urothelial carcinoma.
  • An oral presentation will detail interim analysis results from the Duravelo-2 trial.
  • The presentations will be made available on Bicycle Therapeutics' website starting May 31, 2026.

The big picture

Bicycle Therapeutics is attempting to establish a foothold in the crowded immuno-oncology space with its unique bicyclic peptide technology. The ASCO presentations represent a crucial inflection point for the company, as the data will directly impact the perceived viability of its lead asset, zelenectide pevedotin, and its broader pipeline strategy. Success here could validate the BDC platform, while negative results could significantly impact the company's valuation.

What we're watching

Clinical Efficacy
The oral presentation’s interim analysis results will be critical in assessing the potential of zelenectide pevedotin in combination with pembrolizumab, and will likely influence investor sentiment regarding the Duravelo-2 trial’s overall success.
Monotherapy Potential
The updates on Duravelo-1 will reveal whether zelenectide pevedotin demonstrates sufficient efficacy as a monotherapy, which could broaden its potential market and reduce reliance on combination therapies.
Dosage Optimization
The poster detailing dosage optimization efforts will provide insight into Bicycle Therapeutics' ability to refine the therapeutic window of zelenectide pevedotin and mitigate potential toxicity concerns.

Bicycle Therapeutics Shows Promise in 'Undruggable' EphA2 Target

Event summary

  • Bicycle Therapeutics presented Phase 1/2 data at the AACR Annual Meeting 2026 showing a 40% ORR in EphA2+ mUC patients treated with nuzefatide pevedotin and nivolumab.
  • The company has identified 8mg/m2 Q2W as the preferred dose for monotherapy of nuzefatide in pancreatic cancer.
  • Human imaging data using a Bicycle Imaging Agent (BIA) targeting EphA2 demonstrated rapid tumor uptake and excretion in PDAC patients.
  • Patient enrollment began in March 2026 for a Phase 2 clinical trial evaluating nuzefatide in recurrent PDAC, with the first patient dosed in April 2026.

The big picture

Bicycle Therapeutics' progress in targeting EphA2, a historically 'undruggable' target, represents a significant advancement in oncology drug development. The company's differentiated approach, leveraging its Bicycle® technology, offers a potential alternative to antibody-based therapies that have faced toxicity or efficacy challenges. Success in pancreatic cancer, a disease with limited treatment options, could unlock substantial commercial value and validate the platform for broader application.

What we're watching

Clinical Efficacy
The success of the Phase 2 trial in pancreatic cancer will be critical in validating nuzefatide's potential and driving further development.
Regulatory Pathway
Given the historical difficulty in targeting EphA2, regulatory acceptance of Bicycle's approach will hinge on demonstrating a favorable benefit-risk profile.
Competitive Landscape
The emergence of Bicycle's differentiated approach could attract increased competition in the EphA2-targeted therapy space, potentially impacting market share and pricing.

Bicycle Therapeutics Presents Data on EphA2-Targeted Therapies at AACR 2026

Event summary

  • Bicycle Therapeutics will present five abstracts, including an oral presentation, at the AACR Annual Meeting 2026 in San Diego, April 17-22.
  • The oral presentation focuses on preclinical assessment of BT5528 (nuzefatide pevedotin) in head and neck squamous cell carcinoma (HNSCC) models.
  • Data will also be presented on a Phase 1/2 study combining BT5528 with nivolumab in patients with advanced solid tumors.
  • Research includes preclinical assessment of BT5528 in pancreatic ductal adenocarcinoma (PDAC) models and development of a PET imaging agent targeting EphA2.

The big picture

Bicycle Therapeutics' focus on undruggable targets like EphA2 represents a strategic bet on innovative therapeutic modalities. The AACR presentations provide a critical data update on the progress of nuzefatide pevedotin and other pipeline candidates, which will influence investor sentiment and the company's ability to secure further partnerships or funding. The combination therapy with nivolumab highlights the increasing trend of immuno-oncology approaches in cancer treatment.

What we're watching

Clinical Efficacy
The Phase 1/2 data presented on BT5528 in combination with nivolumab will be crucial in determining the viability of this therapeutic approach and its potential to overcome resistance mechanisms in solid tumors.
Target Validation
The data on EphA2 expression across different cancer subtypes will inform the company's strategy for patient selection and potentially expand the applicability of Bicycle’s EphA2-targeting therapies.
Imaging Potential
The development of a PET imaging agent for EphA2 will likely influence the company’s ability to identify and stratify patients for clinical trials, potentially accelerating drug development timelines.

Bicycle Therapeutics Deprioritizes Key Program, Announces Workforce Reduction

Event summary

  • Bicycle Therapeutics has deprioritized its lead program, zelenectide for mUC, following regulatory feedback indicating the current trial design is not an acceptable approval pathway.
  • The company plans to convert the ongoing Duravelo-2 trial to a randomized Phase 2 study and will seek partners for BT7480.
  • Bicycle Therapeutics is implementing a workforce reduction of approximately 30%, anticipating annual operational savings of roughly 50%.
  • The company expects its cash runway to extend to 2030 following the reprioritization and workforce reduction.
  • Bicycle Therapeutics entered into a 15-year agreement with the UK Nuclear Decommissioning Authority for access to reprocessed uranium to support its radiopharmaceutical pipeline.

The big picture

Bicycle Therapeutics' strategic shift reflects the increasing regulatory scrutiny and high costs associated with oncology drug development. The decision to deprioritize zelenectide, despite promising early data, highlights the challenges faced by smaller biopharma companies in navigating the approval process. The company's focus on radiopharmaceuticals and next-generation therapeutics represents a bet on emerging technologies and potentially higher-value assets, but also introduces new risks and development hurdles.

What we're watching

Regulatory Headwinds
The evolving regulatory landscape for mUC therapies will dictate the timeline and cost of any future zelenectide development, and Bicycle's ability to adapt to these changes will be crucial.
Execution Risk
The success of the randomized Phase 2 trial for zelenectide will be critical in determining whether the program can be revived, and the company's ability to execute this trial efficiently will be key.
Pipeline Focus
The company's ability to successfully advance its next-generation therapeutics, particularly BT5528 and its radioligand pipeline, will determine its long-term viability and ability to attract further investment.

Bicycle Therapeutics Restructures Leadership Amid Pipeline Expansion

Event summary

  • Travis Thompson is appointed CFO, replacing Alethia Young, who will remain as an advisor for three months.
  • Michael Method, M.D., MPH, MBA, is promoted to CMO, succeeding Eric Westin, who transitions to a distinguished fellow role.
  • Michael Skynner becomes Chief Scientific Officer, expanding his responsibilities from Chief Technology Officer.
  • The changes are framed as supporting the company's 2026 priorities and leveraging radiopharmaceutical partnerships.
  • Bicycle Therapeutics projects a financial runway into 2028.

The big picture

Bicycle Therapeutics' leadership reshuffle signals a strategic pivot towards accelerating pipeline development and expanding beyond its initial oncology focus. The appointments, particularly the CFO and CMO, suggest a need to strengthen financial management and clinical execution capabilities as the company navigates a competitive landscape and seeks to capitalize on radiopharmaceutical partnerships. This restructuring comes as the broader biopharma sector faces increased pressure to demonstrate value and efficiency in drug development.

What we're watching

Financial Acumen
The market will assess whether Thompson’s experience in life sciences accounting and investor relations can stabilize the share price and improve capital markets access, particularly given the company’s projected runway.
Clinical Execution
Method’s track record as CMO will be scrutinized as Bicycle advances its BDC and TICA programs through clinical trials, given the inherent risks and high costs associated with oncology drug development.
Scientific Innovation
The success of Skynner’s expanded role will hinge on his ability to drive innovation in Bicycle’s core technology and identify new therapeutic applications beyond oncology, potentially broadening the company’s long-term market opportunity.

Bicycle Therapeutics Secures Radiopharmaceutical Supply Chain via New Partnerships

Event summary

  • Bicycle Therapeutics partnered with the United Kingdom Nuclear Decommissioning Authority, United Kingdom National Nuclear Laboratory, and SpectronRx to establish a potential end-to-end supply chain for 212Pb radiopharmaceuticals.
  • The company reported updated topline Phase 1 data for zelenectide pevedotin plus pembrolizumab in metastatic urothelial cancer, showing promising anti-tumor activity and a differentiated safety profile.
  • Bicycle initiated Phase 1/2 trials for zelenectide pevedotin in NECTIN4-amplified breast cancer and non-small cell lung cancer.
  • Early human imaging data for Bicycle® Radioconjugate (BRC®) molecules targeting EphA2 and MT1-MMP were presented, supporting their potential as cancer targets.

The big picture

Bicycle Therapeutics is attempting to establish a unique position in the radiopharmaceutical market by integrating target identification, drug development, and isotope supply. This vertically integrated approach, while ambitious, aims to mitigate supply chain vulnerabilities that have plagued the sector. The company's success depends on demonstrating clinical efficacy and navigating the complex regulatory landscape for radiotherapeutic agents, a market poised for significant growth as targeted therapies become more prevalent.

What we're watching

Regulatory Approval
The company's ability to secure regulatory approval for zelenectide pevedotin will hinge on the outcome of meetings with agencies and the data presented from the Durvelo-2 trial, potentially impacting its commercial viability.
Clinical Execution
The success of the ongoing Phase 1/2 trials for BT5528 and BT7480 will determine the viability of Bicycle’s broader pipeline and its ability to expand beyond Nectin-4 targeting.
Supply Chain Risk
The nascent radiopharmaceutical supply chain established through the new partnerships will need to scale rapidly and reliably to support potential commercialization, creating a potential bottleneck if demand outstrips supply.
CID: 3885